Skip to Content

DBV Technologies Announces Initiation of Phase III Study of Viaskin(r) Peanut for the Treatment of Peanut Allergic Children

DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced the initiation of a pivotal Phase III study designed to evaluate the safety and efficacy of Viaskin® Peanut 250 micrograms in children ages 4 to 11 with peanut allergy. Click here for more details.